ORIGINAL ARTICLE

Journal of Cachexia, Sarcopenia and Muscle 2021; **12**: 1803–1817
Published online 15 September 2021 in Wiley Online Library (wileyonlinelibrary.com) **DOI:** 10.1002/jcsm.12782

Genetic variation in genes regulating skeletal muscle regeneration and tissue remodelling associated with weight loss in chronic obstructive pulmonary disease

Preeti Lakshman Kumar[1], Ava C. Wilson[1,2], Alison Rocco[1,2], Michael H. Cho[3,4], Emily Wan[3,5], Brian D. Hobbs[3,4], George R. Washko[4], Victor E. Ortega[6], Stephanie A. Christenson[7], Xingnan Li[8], J. Michael Wells[1], Surya P. Bhatt[1], Dawn L. DeMeo[3,4], Sharon M. Lutz[9], Harry Rossiter[10], Richard Casaburi[10], Stephen I. Rennard[11], David A. Lomas[12], Wassim W. Labaki[13], Ruth Tal-Singer[14], Russel P. Bowler[15], Craig P. Hersh[3,4], Hemant K. Tiwari[16], Mark Dransfield[1], Anna Thalacker-Mercer[17], Deborah A. Meyers[8], Edwin K. Silverman[3,4], Merry-Lynn N. McDonald[1,2,18]* & on behalf of the COPDGene, ECLIPSE and SPIROMICS investigators

[1]*Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA;* [2]*Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA;* [3]*Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA;* [4]*Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA;* [5]*Veterans Affairs Boston Health Care System, Jamaica Plain, Boston, MA, USA;* [6]*Department of Internal Medicine, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA;* [7]*Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA;* [8]*Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, USA;* [9]*Department of Population Medicine, Harvard Medical School, Boston, MA, USA;* [10]*Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor Harbor-UCLA Medical Center, Torrance, CA, USA;* [11]*Department of Medicine, Nebraska Medical Center, Omaha, NE, USA;* [12]*UCL Respiratory, University College London, London, UK;* [13]*Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA;* [14]*COPD Foundation, Miami, FL, USA;* [15]*Department of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine, National Jewish Health, Denver, CO, USA;* [16]*Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA;* [17]*Department of Cell Development and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA;* [18]*Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA*

Abstract

Background Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally. COPD patients with cachexia or weight loss have increased risk of death independent of body mass index (BMI) and lung function. We tested the hypothesis genetic variation is associated with weight loss in COPD using a genome-wide association study approach.

Methods Participants with COPD (N = 4308) from three studies (COPDGene, ECLIPSE, and SPIROMICS) were analysed. Discovery analyses were performed in COPDGene with replication in SPIROMICS and ECLIPSE. In COPDGene, weight loss was defined as self-reported unintentional weight loss > 5% in the past year or low BMI (BMI < 20 kg/m^2). In ECLIPSE and SPIROMICS, weight loss was calculated using available longitudinal visits. Stratified analyses were performed among African American (AA) and Non-Hispanic White (NHW) participants with COPD. Single variant and gene-based analyses were performed adjusting for confounders. Fine mapping was performed using a Bayesian approach integrating genetic association results with linkage disequilibrium and functional annotation. Significant gene networks were identified by integrating genetic regions associated with weight loss with skeletal muscle protein–protein interaction (PPI) data.

Results At the single variant level, only the rs35368512 variant, intergenic to *GRXCR1* and *LINC02383*, was associated with weight loss (odds ratio = 3.6, 95% confidence interval = 2.3–5.6, $P = 3.2 \times 10^{-8}$) among AA COPD participants in COPDGene. At the gene level in COPDGene, *EFNA2* and *BAIAP2* were significantly associated with weight loss in AA and NHW COPD participants, respectively. The *EFNA2* association replicated among AA from SPIROMICS (P = 0.0014), whereas the *BAIAP2* association replicated in NHW from ECLIPSE (P = 0.025). The *EFNA2* gene encodes the membrane-bound protein ephrin-A2 involved in the regulation of developmental processes and adult tissue homeostasis such as skeletal muscle. The *BAIAP2* gene encodes the insulin-responsive protein of mass 53 kD (IRSp53), a negative

© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

regulator of myogenic differentiation. Integration of the gene-based findings participants with PPI data revealed networks of genes involved in pathways such as Rho and synapse signalling.

Conclusions The *EFNA2* and *BAIAP2* genes were significantly associated with weight loss in COPD participants. Collectively, the integrative network analyses indicated genetic variation associated with weight loss in COPD may influence skeletal muscle regeneration and tissue remodelling.

Keywords GWAS; Cachexia; Weight loss; COPD; Genetics; Biomarkers; Skeletal muscle regeneration; Tissue remodelling

Received: 21 January 2021; Revised: 8 June 2021; Accepted: 4 August 2021
**Correspondence to: Merry-Lynn McDonald, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 701 19th Street S, LHRB 440, Birmingham, AL 35233, USA. Tel: +1-205-934-0714, Fax: +1-205-934-1721, Email: mmcdonald@uab.edu*

Introduction

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death internationally with associated mortality continuing to rise.[1,2] Although COPD is primarily diagnosed using lung function, traits not directly related to lung function such as cachexia greatly reduce quality of life and increase risk of mortality.[3,4] Cachexia is a debilitating comorbidity increasing risk of death[3] and healthcare expenditure.[5] Most often thought of with respect to cancer, it has been estimated that there are 1.4 times as many patients with COPD cachexia than cancer cachexia by population prevalence.[6]

Cachexia is defined as weight loss, primarily caused by loss of muscle with or without loss of fat, in individuals suffering from a chronic illness.[3] The consensus definition for cachexia diagnosis includes weight loss $>$ 5% in the last 12 months or low body mass index (BMI) (BMI $<$ 20 kg/mg^2) in addition to three out of five of decreased muscle strength; fatigue; anorexia; low fat-free mass index; and any indication of increased inflammatory markers (C-reactive protein, IL6, etc.), anaemia, or low serum albumin.[3] We recently demonstrated participants with COPD with cachexia and/or weight loss greater than 5% in the past year had a greater than three-fold increased mortality independent of BMI and lung function.[4] Monitoring cachexia using weight loss criteria is relatively simple and predictive of mortality among individuals with COPD.

Loss of muscle mass underlying weight loss in cachexia can be influenced by dysregulation of a number of mechanisms involved in the balance between protein synthesis and degradation.[7] Further, impaired ability to regenerate skeletal muscle tissue can contribute to muscle loss in COPD cachexia.[7] COPD patients with advanced disease are more likely to exhibit weight loss[4] in addition to skeletal muscle remodelling from a slow twitch (Type I) to a fast twitch (Type II) myofibre shift.[8] Skeletal muscle remodelling occurs in response to external stimuli leading to activation of intracellular signalling pathways and muscle fibre transition.[9]

Although the major risk factor for COPD is smoking, COPD is a heritable disease with multiple genetic loci reproducibly associated.[10–13] The prevalence of cachexia in COPD is correlated with increasing disease severity.[4] Genetic variation may also contribute to the development of cachexia and weight loss in COPD. By performing genome-wide association study (GWAS) analyses, we previously identified genetic variants associated with longitudinal BMI in a small number of participants with COPD (N = 237) in the Framingham Heart Study.[14] As analyses were performed in a small size, investigation in a larger sample of participants with COPD with more precise phenotyping is merited. The genetics of cachexia have been more thoroughly investigated in cancer with several genes reproducibly associated using primarily candidate gene association approaches.[15,16] Cancer cachexia genes identified in association studies are known to be involved with inflammatory response regulation, pathways directing muscle and fat metabolism and appetite regulation among others.[15,17]

We hypothesized genetic variation may be associated with weight loss contributing to cachexia in COPD. To test this hypothesis, we performed GWAS testing in 4308 participants with COPD from 3 cohorts: COPD Genetic Epidemiology (COPDGene), Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE), and Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Replication was assessed in remaining cohorts. GWAS findings were further explored by integrating gene-based findings with publicly available transcriptomics and protein–protein interaction (PPI) databases to gain additional insight to underlying biological mechanisms which may be influencing cachexia.

Materials and methods

Ethics statement

Institutional Review Board approval for all analyses was obtained from the University of Alabama at Birmingham and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Manuscript complies with the Ethical guidelines for authorship manuscript that they comply with the Ethical guidelines for authorshipand publishing in the Journal of Cachexia, Sarcopenia and Muscle.[18]

Study participants

The current analyses utilized COPD participants recruited as part of three studies: COPDGene,[19] ECLIPSE,[20] and SPIROMICS[21] (Supporting Information, *Figure* S1). In all studies, COPD was classified using post-bronchodilator lung function testing (FEV_1: forced expiratory volume in 1 s and FEV_1/FVC: FEV1 expressed as a fraction of forced vital capacity) at baseline enrolment. All participants with COPD had moderate to severe disease defined by a GOLD[22] stage of 2 (FEV1/FVC < 0.7 and $50\% < FEV_1 < 80\%$ predicted) or higher (GOLD 3 and 4). In the current analyses, COPDGene COPD participants had at least a 10 pack-year smoking history, were aged 45 to 80 years at baseline and followed longitudinally with two visits 5 years apart. In ECLIPSE, COPD participants had at least a 10 pack-year smoking history and were aged 45 to 75 years at baseline and followed longitudinally. Visits in ECLIPSE occurred at baseline, 3 months, 6 months, and then every 6 months for 3 years. In SPIROMICS, COPD participants had at least a 20 pack-year smoking history, were aged 41 to 80 years at baseline, and were followed with annual visits for 3 years.

Weight loss in chronic obstructive pulmonary disease

As diagrammed in *Figure* S1, COPDGene weight loss was defined as either self-reported, unintentional weight loss greater than 5% in the past year, or as had low BMI (<20 kg/m^2). We performed additional cleaning of the self-reported unintentional weight loss variable in COPDGene by confirming weight loss based on the weight measurements collected at Visits 1 and 2. This led to the exclusion of two participants (*Figure* S1). In ECLIPSE and SPIROMICS, weight loss greater than 5% was defined if present at any of the longitudinal visits.

Genome-wide association study analyses

Genotyping in COPDGene was performed using the Illumina Human Omni 1-Quad (Illumina, San Diego, CA), in ECLIPSE using the Illumina HumanHap 550v3 chips and in SPIROMICS using the Illumina HumanOmniExpressExome BeadChip (Illumina, Inc., San Diego, CA). Standard quality control steps were performed on DNA samples and single-nucleotide polymorphism (SNP) data as previously described.[23–25] For all three studies, genotypes were imputed using the Haplotype Reference Consortium reference panel.[26] Only SNPs with an imputation quality score of 0.5 or greater were included in the analysis. SNP positions were reported based on the human genome 19 build. SNPs were annotated to genes or closest genes using the NCBI human genome 19 RefGene database (version 2017-06-01) as implemented using ANNOVAR.[27] In COPDGene, a total of 5,405,435 and 7,629 ,332 variants were imputed and passed quality control in the Non-Hispanic White (NHW) and African American (AA) COPD participants, respectively. In ECLIPSE, a total of 5 370 356 variants were imputed and passed quality control. In SPIROMICS, a total of 5,421,262 variants were imputed and passed quality control in NHW and AA participants. Statistical analyses were performed in PLINK v1.90b3.45[28] and R vfoss/2016b.[29] Discovery analyses were performed using data from AA COPD and NHW COPD participants from COPDGene, and results were assessed in the remaining cohorts for replication. Association with weight loss for each SNP with a minor allele frequency of 5% or greater was tested assuming an additive model adjusting for age, sex, and principal components of genetic ancestry controlling for genetic ancestry. The level of genome-wide significance (GWS) for SNPs association tests was defined as $P < 5.0 \times 10^{-8}$. This level of GWS is a value traditionally used in GWAS to account for the large number of variants in linkage disequilibrium.[30] It approximates a Bonferroni-corrected $P = 0.05$ for one million independent tests in the genome. Regional association plots were generated using LocusZoom[31] and linkage disequilibrium information from the 1000 Genomes African Ancestry and 1000 Genomes European Ancestry reference panels[32] were used. Meta-analyses were performed using the METAL[33] software. Gene-based analyses were performed using the MAGMA[34] software that integrates both single SNP tests with linkage disequilibrium patterns within gene regions. MAGMA assigns SNPs to genes based on physical position (±50 kb) of known genes in the NCBI site. Statistical significance (GWS) for gene-based tests was defined as $P < 2.5 \times 10^{-6}$, which corresponds to Bonferroni-corrected P value threshold for $P = 0.05$ for the approximate 20 000 genes in the genome.

Fine-mapping analysis

To prioritize biological causality of the genotyped variants, fine mapping was performed using PAINTOR.[35] PAINTOR implements a Bayesian approach incorporating genetic association results, linkage disequilibrium, and functional annotation to generate the posterior probability (PP) of causality for each variant. Fine-mapping regions were prioritized based on examination of the regional association plots as well as including variants ±25 kb from the lead variant. Single SNP test statistic (Z score) information from the gene regions for the variants in the partitioned gene regions was used as input and was functionally annotated to the regions in skeletal muscle, lung, brain, adipose, and liver. Top 5 regions functionally annotated to the variants based on highest likelihood ratio were included for the analysis.

DOI: 10.1002/jcsm.12782

Defining modules by integrating genome-wide association study findings with protein–protein interaction data

R library dmGWAS Version 2.4 was used to integrate GWAS findings with PPI data.[36] The dmGWAS algorithm is applied to integrate GWAS results with PPI data by using the PPI data as a search space to examine gene networks also termed modules. Nodes in the network represent gene-based results with edges representing PPI between proteins encoded by two genes. Every gene in the GWAS results is considered as an initial seed gene by the dmGWAS algorithm with a starting test statistic corresponding to the gene-based result. Using the search space defined by the PPI network additional genes are considered for inclusion in the module. A gene is included in the module if it increases the module test statistic by a factor of r. PPI data were downloaded from PINA,[37] which includes collected and annotated data from six public databases: MINT, IntAct, DIP, BioGRID, HPRD, and MIPS/IMPact, on 16 December 2019. We further subset the PPI network data based on proteins in the Compiled Skeletal Muscle Proteome.[38] In the current analyses, gene-based meta-analysis in the AA and NHW COPD participants was used as an input to dmGWAS. A distance constraint of $d = 2$ and $r = 0.1$ were used. A normalized module score accounting for the number of genes in the modules was generated. dmGWAS function simpleChoose was used to choose the top 10 ranked modules based on the normalized module score. Subnetworks created for each ethnicity-based PPI network was visualized using Cytoscape 3.6.1.[39]

Pathway and tissue enrichment analyses

Gene-set enrichment analysis (GSEA)[40] and tissue enrichment analyses was performed using the Functional Mapping and Annotation[41] software to examine known biology of the network modules that were generated by dmGWAS. Tissue enrichment was assessed by testing whether collections of genes exhibit tissue specific expression patterns based on the Genotype-Tissue Expression project Version 8 data[42] implemented in Functional Mapping and Annotation.

Results

Chronic obstructive pulmonary disease population characteristics

We contrasted descriptive characteristics of COPD participants in the discovery cohort, COPDGene, with the replication cohorts, SPIROMICS and ECLIPSE (*Table* 1). When comparing SPIROMICS and COPDGene, SPIROMICS AA COPD participants, on average, were more likely to be older, have lower BMI, have better lung function, and to have unintentional weight loss (*Table* 1). On average, among NHW COPD participants, those in ECLIPSE were more likely to be male participants, have lower BMI, have less smoking exposure, have worse lung function, and have higher unintentional weight loss than those in COPDGene and SPIROMICS (*Table* 1), whereas NHW SPIROMICS subjects tended to be older, on average, compared with COPDGene and ECLIPSE (*Table* 1). The prevalence of weight loss was 17% and 14.6% in COPDGene AA and NHW participants with COPD, respectively, whereas the prevalence of the weight loss trait ranged from 30.7% to 38.6% in SPIROMICS and ECLIPSE COPD participants.

Examining association of single SNPs with weight loss in participants with COPD

Among AA COPD participants, the rs35368512 variant was significantly associated with weight loss in the discovery

Table 1 Characteristics of COPD participants included in GWAS of weight loss

Characteristic, *N* (%)	African Americans			Non-Hispanic Whites			
	COPDGene	SPIROMICS	*P* value*	COPDGene	ECLIPSE	SPIROMICS	*P* value†
N	401	138	—	1380	1569	820	—
Sex (% male)	197 (49.1)	71 (51.4)	0.82	758 (54.9)	1054 (67.2)	466 (56.8)	0.48
Age	58.1 ± 7.5	61.4 ± 8.2	<0.0001	64.1 ± 7.9	63.7 ± 7.0	65.9 ± 7.4	<0.0001
BMI	28.4 ± 6.6	26.7 ± 5.8	0.0076	28.6 ± 5.9	26.8 ± 5.6	27.5 ± 5.2	<0.0001
Pack years	41.6 ± 22.4	42.8 ± 19.5	0.56	53.7 ± 26.1	50.0 ± 27.1	57.2 ± 51.0	<0.0001
FEV1pp	56.4 ± 15.2	53.3 ± 16.6	0.046	54.2 ± 16.2	48.3 ± 15.6†	54.1 ± 16.7	<0.0001
Weight loss[a]	68 (17.0)	50 (36.2)	0.0082	201 (14.6)	605 (38.6)†	252 (30.7)	0.0047

Continuous variables (age, BMI, FEV1pp, and pack-years of smoking) are represented by means and standard deviations.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1pp, forced expiratory volume in 1 s expressed as percentage of predicted; GOLD, Global Initiative for Chronic Obstructive Lung Disease; WL, weight loss.
[a]Weight loss is defined as WL > 5% and/or low BMI at any time point in the study.
*P value generated from χ^2 test statistic for categorical variables and paired test statistic for continuous variables comparing African Americans between COPDGene and SPIROMICS.
†P value generated from χ^2 test statistic for categorical variables and one-way ANOVA test statistic for continuous variables comparing Non-Hispanic Whites between COPDGene, ECLIPSE, and SPIROMICS.

analysis [odds ratio (OR) = 3.6, 95% confidence interval (CI) = 2.3–5.6, $P = 3.2 \times 10^{-8}$, *Table* S1] but did not replicate in the AA COPD participants from SPIROMICS. The rs35368512 variant is intergenic with the closest gene, *GRXCR1*, located within 200 kb (*Figure* 1A). When the meta-analysis results of weight loss in AA COPD participants were examined, no additional variant was associated at a level of GWS (*Table* S2). The top variant associated with weight loss in AA COPD participants in the meta-analysis was intronic to the *TBX15* gene (*Table* S2). Among the NHW COPD participants in COPDGene, no single variant was significantly associated with weight loss (*Table* S3) nor reached GWS in the meta-analysis of all the populations (*Table* S4). The top single variant (rs62015138, OR = 2.1, 95% CI = 1.6–2.8, $P = 6.4 \times 10^{-7}$) associated with weight loss among NHW COPD participants in COPDGene was within the *RBFOX1* gene (*Table* S3). The top single variant associated with weight loss in the meta-analysis of NHW COPD participants (rs35017521, OR = 1.4, 95% CI = 1.2–1.6, $P = 7.7 \times 10^{-7}$, *Table* S4) is intergenic between a microRNA gene (*MIR6072*) and a long intergenic non-protein coding RNA gene (*LINC00701*).

EFNA2 and BAIAP2 gene-based regions associated with weight loss in participants with COPD

At the gene level, *EFNA2* was associated at level of GWS with weight loss among AA COPD participants (*Table* 2). This finding replicated ($P < 0.05$) among AA COPD participants from SPIROMICS contributing to a meta-analysis $P = 1.4 \times 10^{-8}$ (*Table* 2). The lead *EFNA2* variant, chr19:1304013, was associated with an increased risk of weight loss (OR = 3.6, 95% CI = 1.9–6.7, $P = 6.2 \times 10^{-5}$) in discovery analyses, which was not GWS. In the meta-analysis, an additional two genes, *C19orf24* and *CIRBP*, were associated with weight loss at a level of GWS among AA COPD participants (*Table* 2). The *EFNA2* and *CIRBP* genes are located in the same region on chromosome 19 (*Figure* 1B). Fine mapping of 109 variants indicated 41% were needed to obtain a credible set with modest PP. Fine-mapping analyses indicated several variants within *EFNA2* had modest PP of being causal (PP > 0.15, *Figure* 2) with the combined region accounting for 99% of the PP.

Among NHW COPD participants, the *BAIAP2* gene was significantly associated with weight loss (*Table* 3) with the finding replicating in ECLIPSE. Among NHW COPD participants from SPIROMICS, the *BAIAP2* gene was also associated with weight loss at a level near nominal significance ($P = 0.055$) contributing to the significant meta-analysis result ($P = 5.20 \times 10^{-7}$). In the discovery analyses, NHW COPD participants in COPDGene the top *BAIAP2* variant, chr17:79084367, was associated with decreased risk of weight loss in COPD (OR = 0.60, 95% CI = 0.48–0.76, $P = 1.5 \times 10^{-5}$) but not a level of GWS. The *BAIAP2* gene, on chromosome 17, is near (5 kb) to the *AATK* gene (*Figure* 3). The *AATK* gene is physically close but transcribed in the opposite direction with the two genes having overlapping 3′ non-coding regions.[43] The *AATK* gene was significantly associated with weight loss in COPD participants from COPDGene but did not replicate in ECLIPSE or SPIROMICS (*Table* 3). Fine mapping of 477 variants indicated 41% were needed to obtain a credible set with modest posterior probability. Fine-mapping analysis indicated only one variant within *BAIAP2* had a modest PP of being causal with the remaining variants having low likelihood of being causal (PP $< 5\%$, *Figure* 3). However, the collective set which included variants within *AATK* increased the combined likelihood to 99%.

Integrating GWAS findings with PPI data to identify networks of COPD weight loss genes

Chronic obstructive pulmonary disease weight loss consensus networks were generated using unsupervised integration of gene-based meta-analysis results with PPI data of proteins expressed in skeletal muscle. Integration of the meta-analysis weight loss gene-based results from AA COPD participants identified 12,135 modules. A consensus module was generated from the top 10 most significant modules included 29 genes (*Figure* 4, *Table* S5). Several of these genes (*EFNA2*, *CIRBP*, *WDR88*, and *KCNK1*) in the consensus module were among the top 10 most associated with weight loss in AA COPD participants (*Table* 2). GSEA indicated the consensus module genes associated with weight loss in the AA COPD participants were enriched in pathways involved in *NRF1* signalling, adipogenesis, synapse, and RNA metabolism among others (*Table* S6). Integration of the meta-analysis weight loss gene-based results from NHW COPD participants with PPI network data identified 12,168 modules. A consensus network was created from the top 10 most significant modules and was comprised of 36 genes (*Figure* 5, *Table* S7). Of which, several genes (*BAIAP2*, *AATK*, *ZZEF1*, and *RHOB*) were among the top 10 most significantly associated with weight loss in NHW COPD participants (*Table* 3). GSEA results indicated the consensus module genes were enriched in pathways involved in adipogenesis, synapse signalling, Rho GTPase signalling as well as genes in other known other pathways (*Table* S8). Despite having only one gene, *UBC*, common to both the AA and NHW weight loss consensus networks, there were six known gene-sets in common. These were comprised of genes (i) involved in synapse signalling; (ii) involved in formation of the incision complex; (ii) with sites recognized by miR-520D; (iv) involved in protein tagging for modification, sequestration, transport, or degradation; (v) involved in adipocyte differentiation; and (vi) involved in subdivision of chromosomal regions.

The *EFNA2* gene is a member of the set of 16 synapse signalling genes represented in consensus weight loss networks in both AA and NHW COPD participants (combined GO



Figure 1 (*A*) Regional association plot for top weight loss variant region in African American participants from COPDGene near variant, 4:43232667. (*B*) Regional association plot for top weight loss variant region in non-Hispanic White COPD participants from COPDGene on chromosome 19. In both panels, lead SNPs denoted in purple. Colour of remaining SNPs indicates degree of linkage disequilibrium with the lead SNP, as measured by r^2, the squared coefficient of correlation.

Table 2 Based on meta-analysis, top 10 genes associated with weight loss in participants with COPD in African American cohorts (COPDGene and SPIROMICS)

	Meta-analysis						COPDGene AA			SPIROMICS AA		
Gene	CHR	START	STOP	NSNPS	ZSTAT	*P* value	NSNPS	ZSTAT	*P* value	NSNPS	ZSTAT	*P* value
EFNA2[a]	19	1236153	1351430	252	5.6	1.40E-08	270	4.7	1.34E-06	233	3.0	1.42E-03
C19orf24	19	1225520	1329243	220	5.2	1.20E-07	237	4.5	4.00E-06	202	2.6	4.59E-03
CIRBP[a]	19	1219267	1324809	221	4.6	2.10E-06	235	4.1	1.74E-05	206	2.0	2.10E-02
WI2-2373I1.2	7	280136	384388	100	3.9	4.80E-05	81	4.6	2.16E-06	119	−0.1	5.49E-01
WDR88[a]	19	33572949	33717830	434	3.8	6.10E-05	435	2.2	1.43E-02	432	3.9	5.74E-05
KCNK1[a]	1	233699750	233858258	505	3.8	6.30E-05	515	3.3	5.50E-04	495	2.0	2.19E-02
TET2	4	106017032	106250960	477	3.7	1.30E-04	481	2.8	2.55E-03	473	2.5	7.01E-03
OR13C8	9	107281449	107382411	390	3.5	1.90E-04	391	4.4	5.86E-06	388	−0.5	6.77E-01
BTNL3	5	180365845	180483727	258	3.5	2.60E-04	239	3.3	4.40E-04	276	1.2	1.18E-01
MAGI2	7	77596374	79133121	5017	3.5	2.70E-04	5142	3.4	3.26E-04	4892	1.0	1.53E-01

COPD, chronic obstructive pulmonary disease.
[a]Denotes genes that appear in the consensus network.



Figure 2 Fine mapping of *EFNA2* region associated with weight loss among African American COPD participants. (*A*) Scatterplot of location vs. posterior probabilities with credible set, (*B*) physical position of *EFNA2*, and (*C*) functional annotation tracks.

Table 3 Top 10 genes associated with weight loss in participants with COPD based on meta-analysis in non-Hispanic White cohorts (COPDGene, ECLIPSE, and SPIROMICS)

	Meta-analysis						COPDGene NHW			ECLIPSE			SPIROMICS NHW		
Gene	CHR	START	STOP	NSNPS	ZSTAT	*P*	NSNPS	ZSTAT	*P*	NSNPS	ZSTAT	*P*	NSNPS	ZSTAT	*P*
BAIAP2[a]	17	78958944	79141232	578	4.9	5.20E-07	581	4.8	9.83E-07	577	2.0	2.54E-02	577	1.6	5.50E-02
C8orf48	8	13374352	13475797	440	4.3	8.60E-06	434	1.5	6.28E-02	444	2.8	2.81E-03	442	3.4	3.42E-04
AATK[a]	17	79034285	79189877	400	4.1	1.90E-05	392	4.6	2.50E-06	393	1.6	6.01E-02	416	0.8	2.22E-01
ZZEF1[a]	17	3857739	4096314	644	3.8	7.00E-05	642	2.7	3.79E-03	644	2.2	1.57E-02	645	1.7	4.25E-02
CACNG6	19	54444403	54565920	314	3.7	1.30E-04	315	2.3	9.99E-03	316	2.3	1.10E-02	312	1.6	4.95E-02
SEMA5A	5	8985138	9596233	1431	3.5	2.10E-04	1395	1.9	3.09E-02	1461	3.7	9.64E-05	1437	0.0	5.07E-01
UGT2A3	4	69744177	69867509	381	3.5	2.20E-04	380	0.9	1.87E-01	381	2.5	5.65E-03	381	2.9	1.96E-03
RHOB[a]	2	20596835	20699201	290	3.5	2.70E-04	291	2.3	9.67E-03	289	1.8	4.00E-02	291	2.0	2.55E-02
ENPP1	6	132079156	132266295	329	3.4	3.20E-04	335	3.7	1.04E-04	335	1.4	8.78E-02	317	0.6	2.62E-01
ASB5	4	177084824	177248722	472	3.4	3.30E-04	473	3.6	1.48E-04	471	1.3	1.02E-01	472	0.9	1.97E-01

COPD, chronic obstructive pulmonary disease.
[a]Denotes genes that appear in the consensus network.

SYNAPSE gene list in *Tables* S6 and S8). The 16 genes include *STXBP3*, *DISC1*, *KCNK1*, *KPNA2*, *ITSN1*, and *PPP2CA* as well as *PPP1CA*, *SNAP23*, *NSF*, *ELAVL1*, *BIN1*, *PACSIN2*, *ARL8B*, *STX7*, and *STXBP5* in the AA and NHW COPD weight loss consensus networks, respectively. Tissue specificity analyses indicated genes were significantly down-regulated in the liver ($P < 1 \times 10^{-4}$). Further, five of these genes (*KCNK1*, *ELAVL1*, *ARL8B*, *PPP2CA*, and *STXBP5*) also have sites recognized by the miRNA520D (GSEA adjusted $P = 2.1 \times 10^{-5}$).

Discussion

In the current report, we identified two genes significantly associated with weight loss in COPD: *EFNA2* and *BAIAP2*. Although, *EFNA2* and *BAIAP2* were associated with weight loss in COPD among AA and NHW participants, respectively, they were also members of the COPD weight loss consensus networks. This indicates there is genetic variation in these genes that could influence other genes within the same network. As COPD and weight loss are complex traits, we expect genetic variation in many genes contribute to dysregulation at the pathway level. Importantly, many of the gene-sets enriched in the COPD weight loss consensus networks have important roles in skeletal muscle regeneration and tissue remodelling.

The *EFNA2* gene encodes the membrane-bound protein ephrin-A2. Ephrins interact with Eph receptors via contact-dependent cell–cell signalling regulating developmental processes and adult tissue homeostasis.[44] Interestingly, ephrin-A2 participates in bidirectional signalling by activating eph receptors on neighbouring cells as well as its own downstream pathways and has been shown to negatively regulate progenitor cell proliferation.[45] The *EFNA2* gene is a member of the GO SYNAPSE gene-set whose members were represented in both the AA and NHW COPD weight loss consensus networks of genes. We demonstrated using Genotype-Tissue Expression data the 15 COPD weight loss genes in the SYNAPSE gene-set are down-regulated in the liver. The role in the liver is interesting as in metabolic disturbances have been shown to start in the liver before progressing to adipose and skeletal muscle tissues in mouse cancer cachexia models.[46,47] Further, the liver has afferent and efferent neurons which may influence appetite and hormone signals.[48] However, we were not able to test whether genetic variation associated with weight loss in COPD leads to altered gene expression of these 15 genes in the liver. Therefore, additional research into whether expression of these genes is up-regulated in the liver with COPD cachexia and weight loss is needed.

The *BAIAP2* gene encodes the insulin-responsive protein of mass 53 kD (IRSp53), which is an adaptor protein primarily known for its role in modulating actin dynamics and membrane protrusions in cell to cell signalling.[49] Impaired skeletal



Figure 3 Fine mapping of *BAIAP2* region associated with weight loss among non-Hispanic White COPD participants. (*A*) Scatterplot of location vs. posterior probabilities with credible set, (*B*) physical position of genes including *BAIAP2* in region, and (*C*) functional annotation tracks.

muscle regeneration is one mechanism contributing to skeletal muscle loss in cachexia.[50] IRSp53 can act as a negative regulator of myogenic differentiation influencing the development of skeletal muscle as well skeletal muscle regeneration.[50] Previous research demonstrated COPD patients may exhibit heterogeneous and distinct skeletal muscle molecular biomarker patterns in response to pulmonary rehabilitation.[51] However, IRSp53 was not among the biomarkers investigated in the previous research.[51] It is possible dysregulation of IRSp53 may be one mechanism contributing to impaired ability to regenerate skeletal muscle in cachexia; however, this requires further research. Also, GSEA analyses highlighted *BAIAP2* involvement in Rho signalling. Activation of the Rho signalling pathway is required for the maintenance of myotubes.[52] Interestingly, ephrins such as ephrin-B whose gene were associated with weight loss among AA COPD participants activate eph receptors who exert downstream by regulating Rho GTPase signalling.[44]

Our study has many strengths but also limitations. Strengths of the study include a large sample size of COPD participants in multiple cohorts followed longitudinally with weight loss and genotype data available. We also used innovative network methods, going beyond generating a list of genes associated with weight loss in COPD, providing



Figure 4 COPD weight loss consensus network generated from African American participant analyses. Node size is proportional to *P* value significance where the bigger the node size the smaller the *P* value from the gene-based meta-analysis result. Nodes (circles) represent genes that are among the top genes in the consensus network. Edges (lines) are known protein–protein (PPI) interactions. Nodes filled in black represent genes robust to exclusion of UBC from the PPI network.

rationales for further mechanistic research. Limitations of the study include heterogeneity in number of visits used to define weight loss in the discovery and replication cohorts. In COPDGene, a self-reported unintentional weight loss greater than 5% in the past year or low BMI collected at a single visit was used. Whereas in ECLIPSE and SPIROMICS, weight loss and BMI were measured at several annual visits. The prevalence of weight loss was higher in ECLIPSE and SPIROMICS which may be due to increased opportunities for observing weight loss over the course of the study. In COPDGene, weight loss was also unintentional whereas in the other two studies participants may have been intentionally trying to lose weight which could inflate the prevalence of weight loss. Self-reported, unintentional weight loss is likely a more conservative measure, however, may also be subject to recall bias. Discovery analyses were performed using more strict criteria to code the weight loss trait which would have biased findings towards the null. However, the lower number of visits over larger time intervals in COPDGene likely led to misclassification and loss of follow-up of participants with COPD who passed away before weight loss could be recorded by the study. This would have limited our ability to identify some true associations with weight loss in COPD using COPDGene as discovery. Future studies of weight loss in COPD should aim to collect weight measurements more frequently such as the intervals employed in ECLIPSE and SPIROMICS. Further, we also employed a Bonferroni-corrected level of significance to gene-based findings which may have been overly conservative.

Furthermore, the *UBC* gene encoding Ubiquitin C was the only gene in common between the AA and NHW COPD weight loss consensus networks. The ubiquitin-proteasome system is fundamental to muscle atrophy in cachexia.[53] However, we previously demonstrated the network analysis method, dmGWAS, was sensitive to hub genes such as UBC, encoding Ubiquitin C.[54] For these reasons, we also performed the network analyses excluding *UBC* and found *EFNA2* and *BAIPA2* were robustly included in each consensus module whether UBC was included in the PPI search space or not. Finally, we analysed genotyped and imputed SNP data, which led to the identification of two gene regions associated with weight loss in COPD rather than specific genetic variants. We maximized the information in the regions through our fine-mapping approach. Although we analysed a combined



Figure 5 COPD weight loss consensus network generated from non-Hispanic White participant analyses. Node size is proportional to *P* value significance where the bigger the node size the smaller the *P* value from the gene-based meta-analysis result. Nodes (circles) represent genes that are among the top genes in the consensus network. Edges (lines) are known protein–protein (PPI) interactions. Nodes filled in black represent genes robust to exclusion of UBC from the PPI network.

set of 4308 subject with COPD in the three studies combined, the samples sizes became small when stratified by study and ancestry group likely limiting the power to replicate findings in the discovery. For example, the top variant associated with weight loss in the meta-analysis of AA COPD subjects is intronic to the *TBX15* gene. *TBX15* is a member of the T-box family of transcription factors and has been previously associated with waist to hip to ratio.[55] Nonetheless, we were able to maximize information using our integrative approach to discover new aetiology for weight loss in COPD. However, an expanded analysis in these populations of COPD participants using whole-genome sequence with integration with other omics data may lead to data identifying specific genetic variants, which may guide personalize medicine approaches.

To summarize, *BAIAP2* and *EFNA2* genes were significantly associated with weight loss in COPD among NHW and AA participants. Our integrative network analyses identified COPD weight loss genes enriched with genes involved in skeletal muscle regeneration and tissue remodelling as well as providing rationales for further mechanistic research. Identification of genetic variation contributing to weight loss in COPD due to impaired skeletal muscle regeneration and tissue remodelling may enable discovery of therapies that could enhance response to pulmonary rehabilitation.

Acknowledgements

COPDGene® Investigators—Core Units

Administrative Center: James D. Crapo, MD (PI); Edwin K. Silverman, MD, PhD (PI); Barry J. Make, MD; Elizabeth A. Regan, MD, PhD. *Genetic Analysis Center*: Terri Beaty, PhD; Ferdouse Begum, PhD; Peter J. Castaldi, MD, MSc; Michael Cho, MD; Dawn L. DeMeo, MD, MPH; Adel R. Boueiz, MD; Marilyn G. Foreman, MD, MS; Eitan Halper-Stromberg; Lystra P. Hayden, MD, MMSc; Craig P. Hersh, MD, MPH; Jacqueline Hetmanski, MS, MPH; Brian D. Hobbs, MD; John E. Hokanson, MPH, PhD; Nan Laird, PhD; Christoph Lange, PhD; Sharon M. Lutz, PhD; Merry-Lynn McDonald, PhD; Margaret M. Parker, PhD; Dmitry Prokopenko, PhD; Dandi Qiao, PhD; Elizabeth A. Regan, MD, PhD; Phuwanat Sakornsakolpat, MD; Edwin K. Silverman, MD, PhD; Emily S. Wan, MD; Sungho Won, PhD. *Imaging Center*: Juan Pablo Centeno; Jean-Paul

Charbonnier, PhD; Harvey O. Coxson, PhD; Craig J. Galban, PhD; MeiLan K. Han, MD, MS; Eric A. Hoffman, Stephen Humphries, PhD; Francine L. Jacobson, MD, MPH; Philip F. Judy, PhD; Ella A. Kazerooni, MD; Alex Kluiber; David A. Lynch, MB; Pietro Nardelli, PhD; John D. Newell, Jr., MD; Aleena Notary; Andrea Oh, MD; Elizabeth A. Regan, MD, PhD; James C. Ross, PhD; Raul San Jose Estepar, PhD; Joyce Schroeder, MD; Jered Sieren; Berend C. Stoel, PhD; Juerg Tschirren, PhD; Edwin Van Beek, MD, PhD; Bram van Ginneken, PhD; Eva van Rikxoort, PhD; Gonzalo Vegas Sanchez-Ferrero, PhD; Lucas Veitel; George R. Washko, MD; Carla G. Wilson, MS. *PFT QA Center, Salt Lake City, UT*: Robert Jensen, PhD. *Data Coordinating Center and Biostatistics, National Jewish Health, Denver, CO*: Douglas Everett, PhD; Jim Crooks, PhD; Katherine Pratte, PhD; Matt Strand, PhD; Carla G. Wilson, MS. *Epidemiology Core, University of Colorado Anschutz Medical Campus, Aurora, CO*: John E. Hokanson, MPH, PhD; Gregory Kinney, MPH, PhD; Sharon M. Lutz, PhD; Kendra A. Young, PhD. *Mortality Adjudication Core:* Surya P. Bhatt, MD; Jessica Bon, MD; Alejandro A. Diaz, MD, MPH; MeiLan K. Han, MD, MS; Barry Make, MD; Susan Murray, ScD; Elizabeth Regan, MD; Xavier Soler, MD; Carla G. Wilson, MS. *Biomarker Core*: Russell P. Bowler, MD, PhD; Katerina Kechris, PhD; Farnoush Banaei-Kashani, PhD.

COPDGene® Investigators—Clinical Centres

Ann Arbor VA: Jeffrey L. Curtis, MD; Perry G. Pernicano, MD. *Baylor College of Medicine, Houston, TX*: Nicola Hanania, MD, MS; Mustafa Atik, MD; Aladin Boriek, PhD; Kalpatha Guntupalli, MD; Elizabeth Guy, MD; Amit Parulekar, MD. *Brigham and Women's Hospital, Boston, MA*: Dawn L. DeMeo, MD, MPH; Alejandro A. Diaz, MD, MPH; Lystra P. Hayden, MD; Brian D. Hobbs, MD; Craig Hersh, MD, MPH; Francine L. Jacobson, MD, MPH; George Washko, MD. *Columbia University, New York, NY*: R. Graham Barr, MD, DrPH; John Austin, MD; Belinda D'Souza, MD; Byron Thomashow, MD. *Duke University Medical Center, Durham, NC*: Neil MacIntyre, Jr., MD; H. Page McAdams, MD; Lacey Washington, MD. *Grady Memorial Hospital, Atlanta, GA*: Eric Flenaugh, MD; Silanth Terpenning, MD. *HealthPartners Research Institute, Minneapolis, MN*: Charlene McEvoy, MD, MPH; Joseph Tashjian, MD. *Johns Hopkins University, Baltimore, MD*: Robert Wise, MD; Robert Brown, MD; Nadia N. Hansel, MD, MPH; Karen Horton, MD; Allison Lambert, MD, MHS; Nirupama Putcha, MD, MHS. *Lundquist Institute for Biomedical Innovationat Harbor UCLA Medical Center, Torrance, CA*: Richard Casaburi, PhD, MD; Alessandra Adami, PhD; Matthew Budoff, MD; Hans Fischer, MD; Janos Porszasz, MD, PhD; Harry Rossiter, PhD; William Stringer, MD. *Michael E. DeBakey VAMC, Houston, TX*: Amir Sharafkhaneh, MD, PhD; Charlie Lan, DO. *Minneapolis VA:* Christine Wendt, MD; Brian Bell, MD; Ken M. Kunisaki, MD, MS. *National Jewish Health, Denver, CO*: Russell Bowler, MD, PhD; David A. Lynch, MB. *Reliant Medical Group, Worcester, MA*: Richard Rosiello, MD; David Pace, MD. *Temple University, Philadelphia, PA:* Gerard Criner, MD; David Ciccolella, MD; Francis Cordova, MD; Chandra Dass, MD; Gilbert D'Alonzo, DO; Parag Desai, MD; Michael Jacobs, PharmD; Steven Kelsen, MD, PhD; Victor Kim, MD; A. James Mamary, MD; Nathaniel Marchetti, DO; Aditi Satti, MD; Kartik Shenoy, MD; Robert M. Steiner, MD; Alex Swift, MD; Irene Swift, MD; Maria Elena Vega-Sanchez, MD. *University of Alabama, Birmingham, AL:* Mark Dransfield, MD; William Bailey, MD; Surya P. Bhatt, MD; Anand Iyer, MD; Hrudaya Nath, MD; J. Michael Wells, MD. *University of California, San Diego, CA*: Douglas Conrad, MD; Xavier Soler, MD, PhD; Andrew Yen, MD. *University of Iowa, Iowa City, IA*: Alejandro P. Comellas, MD; Karin F. Hoth, PhD; John Newell, Jr., MD; Brad Thompson, MD. *University of Michigan, Ann Arbor, MI:* MeiLan K. Han, MD MS; Ella Kazerooni, MD MS; Wassim Labaki, MD MS; Craig Galban, PhD; Dharshan Vummidi, MD. *University of Minnesota, Minneapolis, MN*: Joanne Billings, MD; Abbie Begnaud, MD; Tadashi Allen, MD. *University of Pittsburgh, Pittsburgh, PA*: Frank Sciurba, MD; Jessica Bon, MD; Divay Chandra, MD, MSc; Carl Fuhrman, MD; Joel Weissfeld, MD, MPH. *University of Texas Health, San Antonio, San Antonio, TX*: Antonio Anzueto, MD; Sandra Adams, MD; Diego Maselli-Caceres, MD; Mario E. Ruiz, MD; Harjinder Singh.

SPIROMICS

The authors thank the SPIROMICS participants and participating physicians, investigators, and staff for making this research possible. More information about the study and how to access SPIROMICS data are available at http://www.spiromics.org. The authors would like to acknowledge the University of North Carolina at Chapel Hill BioSpecimen Processing Facility for sample processing, storage, and sample disbursements (http://bsp.web.unc.edu/). We would like to acknowledge the following current and former investigators of the SPIROMICS sites and reading centres: Neil E Alexis, MD; Wayne H Anderson, PhD; Mehrdad Arjomandi, MD; Igor Barjaktarevic, MD, PhD; R Graham Barr, MD, DrPH; Patricia Basta, PhD; Lori A Bateman, MSc; Surya P Bhatt, MD; Eugene R Bleecker, MD; Richard C Boucher, MD; Russell P Bowler, MD, PhD; Stephanie A Christenson, MD; Alejandro P Comellas, MD; Christopher B Cooper, MD, PhD; David J Couper, PhD; Gerard J Criner, MD; Ronald G Crystal, MD; Jeffrey L Curtis, MD; Claire M Doerschuk, MD; Mark T Dransfield, MD; Brad Drummond, MD; Christine M Freeman, PhD; Craig Galban, PhD; MeiLan K Han, MD, MS; Nadia N Hansel, MD, MPH; Annette T Hastie, PhD; Eric A Hoffman, PhD; Yvonne Huang, MD; Robert J Kaner, MD; Richard E Kanner, MD; Eric C Kleerup, MD; Jerry A Krishnan, MD, PhD; Lisa M LaVange, PhD; Stephen C Lazarus, MD; Fernando J

Martinez, MD, MS; Deborah A Meyers, PhD; Wendy C Moore, MD; John D Newell Jr, MD; Robert Paine, III, MD; Laura Paulin, MD, MHS; Stephen P Peters, MD, PhD; Cheryl Pirozzi, MD; Nirupama Putcha, MD, MHS; Elizabeth C Oelsner, MD, MPH; Wanda K O'Neal, PhD; Victor E Ortega, MD, PhD; Sanjeev Raman, MBBS, MD; Stephen I. Rennard, MD; Donald P Tashkin, MD; J Michael Wells, MD; Robert A Wise, MD; and Prescott G Woodruff, MD, MPH. The project officers from the Lung Division of the National Heart, Lung, and Blood Institute were Lisa Postow, PhD, and Lisa Viviano.

Conflict of interest

R.T-S. is a former employee and current shareholder of GSK the sponsor of the ECLIPSE study. She declares personal fees from Immunomet, Vocalis Health, Ena Respiratory and Teva. E.K.S. has received institutional grant support from GSK and Bayer. M.W. has received institutional grant support from Mereo BioPharma, Grifols, Vertex Pharmaceuticals, Bayer AG, ARCUS-Med, Verona, and has been in consultancy roles for AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, and Takeda. G.R.W. has received institutional grant support from Janssen Pharmaceuticals and Boehringer Ingelheim and has been in consultancy roles for Boehringer Ingelheim, CSL Behring, Janssen Pharmaceuticals, Novartis and Vertex. G.R.W. is also a founder and equity holder of Quantitative Imaging Solutions, a data and image analytics company. W.W.L. reports grants from NIH/NHLBI, non-financial support from Pulmonx and personal fees from Konica Minolta. M.H.C. has received grant funding from Bayer and GSK and speaking or consulting fees from Genentech, AstraZeneca, and Illumina. H.B.R. received institutional grant support from GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim and consultancy fees from Boehringer Ingelheim, Astellas Pharma and Omniox Inc. M.T.D. reports grants from NIH, Department of Defense, and the American Lung Association; contracted clinical trial support from AstraZeneca, Boehringer Ingelheim, Boston Scientific, Gala, GlaxoSmithKline, Nuvaira, PneumRx/BTG, and Pulmonx; travel from Pulmonx; and consulting fees from AstraZeneca, GlaxoSmithKline, Mereo, Quark, and Teva.

Funding

M.N.M. is funded by the National Institutes of Health (NIH) (R00HL121087, R56HL153460 and R01HL153460) and the Parker B. Francis Fellowship programme. D.A.L. is funded by the National Institute for Health Research (NIHR)/University College Hospitals (UCLH) Biomedical Research Centre (BRC); he is an NIHR senior investigator. M.H.C. is funded by NIH (R01HL135142, R01 HL137927, and R01 HL14714). B.D.H. is funded by NIH (K08 HL136928). The COPDGene study was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. COPDGene is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. SPIROMICS was supported by contracts from the National Institutes of Health/National Heart, Lung, and Blood Institute (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268 200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), grants from the NIH/NHLBI (U01 HL137880 and U24 HL141762), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; Novartis Pharmaceuticals Corporation; Nycomed GmbH; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan.

Online supplementary material

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. COPD GOLD Stage> = 2 participants with phenotype and genotype data included in analyses. A) COPD participants included from the COPDGene study; B) COPD participants included from SPIROMICS study; C) COPD participants included from ECLIPSE study. GWAS – Genome Wide Association Study. In COPDGene, 2 subjects with Visit 2 self-reported weight loss data were excluded for being incongruent with Visit 1 weight.

Table S1. SNPs associated with COPD weight loss among African American COPD participants from COPDGene (N = 401) with $P < 1E\text{-}5$.

Table S2. Top 10 SNPs associated with weight loss among African American COPD participants based on meta-analysis COPDGene and SPIROMICS.

Table S3. SNPs associated with COPD weight loss among Non-Hispanic White COPD participants from COPDGene with $P < 1E\text{-}5$.

Table S4. Top 10 SNPs associated with weight loss among Non-Hispanic White COPD participants based on meta-analysis of three studies (ECLIPSE, COPDGene and SPIROMICS).

Table S5. Genes represented in the COPD weight loss consensus network from African American participants with corresponding gene-based results provided.

Table S6. Gene Set Enrichment Analysis of Consensus Network Genes associated with weight loss among AA COPD participants from COPDGene and SPIROMICS.

Table S7. Genes represented in the COPD weight loss consensus network from non-Hispanic White participants with corresponding gene-based results provided.

Table S8. Gene Set Enrichment Analysis of Consensus Network Genes associated with weight loss among NHW COPD participants from COPDGene, SPIROMICS and ECLIPSE.

References

1. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2013;**187**: 347–365.
2. Xu J, Murphy SL, Kochanek KD, Bastian B, Arias E. Deaths: final data for 2016. *Natl Vital Stat Rep* 2018;**67**:1–76.
3. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. *Clin Nutr* 2008;**27**:793–799.
4. McDonald MN, Wouters EFM, Rutten E, Casaburi R, Rennard SI, Lomas DA, et al. It's more than low BMI: prevalence of cachexia and associated mortality in COPD. *Respir Res* 2019;**20**:100.
5. Arthur ST, Noone JM, Van Doren BA, Roy D, Blanchette CM. One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA. *Drugs Context* 2014;**3**:212265.
6. von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. *J Cachexia Sarcopenia Muscle*. 2014;**5**:261–263. https://doi.org/10.1007/s13539-014-0164-8
7. Remels AH, Gosker HR, Langen RC, Schols AM. The mechanisms of cachexia underlying muscle dysfunction in COPD. *J Appl Physiol (1985)* 2013;**114**:1253–1262.
8. Gosker HR, Zeegers MP, Wouters EFM, Schols AMWJ. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. *Thorax* 2007;**62**:944–949.
9. Bassel-Duby R, Olson EN. Signaling pathways in skeletal muscle remodeling. *Annu Rev Biochem* 2006;**75**:19–37.
10. Hobbs BD, de Jong K, Lamontagne M, Bossé Y, Shrine N, Artigas MS, et al. Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. *Nat Genet* 2017;**49**:426–432.
11. Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo DL, et al. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. *Hum Mol Genet* 2012;**21**: 947–957.
12. Prokopenko D, Sakornsakolpat P, Fier HL, Qiao D, Parker MM, Mcdonald ML, et al. Whole-genome sequencing in severe chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 2018;**59**:614–622.
13. Jackson VE, Ntalla I, Sayers I, Morris R, Whincup P, Casas JP, et al. Exome-wide analysis of rare coding variation identifies novel associations with COPD and airflow limitation in MOCS3, IFIT3 and SERPINA12. *Thorax* 2016;**71**:501–509.
14. Mcdonald M-LN, Won S, Mattheisen M, Castaldi PJ, Cho MH, Rutten E, et al. Body mass index change in gastrointestinal cancer and chronic obstructive pulmonary disease is associated with dedicator of cytokinesis 1. *J Cach Sarcop Muscle* 2017; 1–9.
15. European Palliative Care Research Collaborative, Tan BHL, Ross JA, Kaasa S, Skorpen F, Fearon KCH. Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review. *J Genet* 2011;**90**:165–177.
16. Johns N, Tan BH, MacMillan M, Solheim TS, Ross JA, Baracos VE, et al. Genetic basis of interindividual susceptibility to cancer cachexia: selection of potential candidate gene polymorphisms for association studies. *J Genet* 2014;**93**:893–916.
17. Johns N, Stretch C, Tan BH, Solheim TS, Sørhaug S, Stephens NA, et al. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. *J Cachexia Sarcopenia Muscle* 2017;**8**:122–130.
18. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2019. *J Cachexia Sarcopenia Muscle* 2019;**10**:1143–1145.
19. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, et al. Genetic epidemiology of COPD (COPDGene) study design. *COPD* 2010;**7**:32–43.
20. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). *Eur Respir J* 2008;**31**:869–873.
21. Hansel NN, Paulin LM, Gassett AJ, Peng RD, Alexis N, Fan VS, et al. Design of the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) AIR Study. *BMJ Open Respir Res* 2017;**4**:e000186.
22. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD executive summary. *Respirology* 2017;**22**:575–601.
23. Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh CP, et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. *Nat Genet* 2010;**42**:200–202.
24. Zhou W, Nielsen JB, Fritsche LG, Dey R, Gabrielsen ME, Wolford BN, et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nat Genet* 2018;**50**:1335–1341.
25. Cho MH, Mcdonald ML, Zhou X, Mattheisen M, Castaldi PJ, Hersh CP, et al. Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. *Lancet Respir Med* 2014;**2**:214–225.
26. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* 2016;**48**: 1279–1283.
27. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010;**38**:e164.
28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007;**81**:559–575.
29. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res* 2012;**40**:D930–D934.
30. Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. *Genet Epidemiol* 2008;**32**:381–385.
31. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* 2010;**26**: 2336–2337.
32. 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature* 2015;**526**:68–74.
33. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 2010;**26**: 2190–2191.
34. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized

gene-set analysis of GWAS data. *PLoS Comput Biol* 2015;**11**:e1004219.
35. Kichaev G, Yang WY, Lindstrom S, Hormozdiari F, Eskin E, Price AL, et al. Integrating functional data to prioritize causal variants in statistical fine-mapping studies. *PLoS Genet* 2014;**10**:e1004722.
36. Jia P, Zheng S, Long J, Zheng W, Zhao Z. dmGWAS: dense module searching for genome-wide association studies in protein-protein interaction networks. *Bioinformatics* 2011;**27**:95–102.
37. Wu J, Vallenius T, Ovaska K, Westermarck J, Mäkelä TP, Hautaniemi S. Integrated network analysis platform for protein-protein interactions. *Nat Methods* 2009;**6**:75–77.
38. Gonzalez-Freire M, Semba RD, Ubaida-Mohien C, Fabbri E, Scalzo P, Højlund K, et al. The Human Skeletal Muscle Proteome Project: a reappraisal of the current literature. *J Cachexia Sarcopenia Muscle* 2017;**8**:5–18.
39. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 2003;**13**:2498–2504.
40. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;**102**:15545–15550.
41. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* 2017;**8**:1826.
42. Consortium GT. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013;**45**:580–585.
43. Miyahara A, Okamura-Oho Y, Miyashita T, Hoshika A, Yamada M. Genomic structure and alternative splicing of the insulin receptor tyrosine kinase substrate of 53-kDa protein. *J Hum Genet* 2003;**48**:410–414.
44. Lisabeth EM, Falivelli G, Pasquale EB. Eph receptor signaling and ephrins. *Cold Spring Harb Perspect Biol* 2013;**5**.
45. Holmberg J, Armulik A, Senti KA, Edoff K, Spalding K, Momma S, et al. Ephrin-A2 reverse signaling negatively regulates neural progenitor proliferation and neurogenesis. *Genes Dev* 2005;**19**:462–471.
46. Halle JL, Pena GS, Paez HG, Castro AJ, Rossiter HB, Visavadiya NP, et al. Tissue-specific dysregulation of mitochondrial respiratory capacity and coupling control in colon-26 tumor-induced cachexia. *Am J Physiol Regul Integr Comp Physiol* 2019;**317**:R68–R82.
47. Khamoui AV, Tokmina-Roszyk D, Rossiter HB, Fields GB, Visavadiya NP. Hepatic proteome analysis reveals altered mitochondrial metabolism and suppressed acyl-CoA synthetase-1 in colon-26 tumor-induced cachexia. *Physiol Genomics* 2020;**52**:203–216.
48. Jensen KJ, Alpini G, Glaser S. Hepatic nervous system and neurobiology of the liver. *Compr Physiol* 2013;**3**:655–665.
49. Scita G, Confalonieri S, Lappalainen P, Suetsugu S. IRSp53: crossing the road of membrane and actin dynamics in the formation of membrane protrusions. *Trends Cell Biol* 2008;**18**:52–60.
50. Misra A, George B, Rajmohan R, Jain N, Wong MH, Kambadur R, et al. Insulin receptor substrate protein 53kDa (IRSp53) is a negative regulator of myogenic differentiation. *Int J Biochem Cell Biol* 2012;**44**:928–941.
51. Kneppers AEM, Haast RA, Langen RC, Verdijk LB, Leermakers PA, Gosker HR, et al. Distinct skeletal muscle molecular responses to pulmonary rehabilitation in chronic obstructive pulmonary disease: a cluster analysis. *J Cach Sarcop Muscle* 2019;**10**:311–322.
52. Wallace MA, Hock MB, Hazen BC, Kralli A, Snow RJ, Russell AP. Striated muscle activator of Rho signalling (STARS) is a PGC-1alpha/oestrogen-related receptor-alpha target gene and is upregulated in human skeletal muscle after endurance exercise. *J Physiol* 2011;**589**:2027–2039.
53. Sanders KJC, Kneppers AEM, van de Bool C, Langen RCJ, Schols AMWJ. Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective. *J Cachexia Sarcopenia Muscle* 2016;**7**:5–22.
54. McDonald ML, Mattheisen M, Cho MH, Liu YY, Harshfield B, Hersh CP, et al. Beyond GWAS in COPD: probing the landscape between gene-set associations, genome-wide associations and protein-protein interaction networks. *Hum Hered* 2015;**78**:131–139.
55. Heid IM, Jackson AU, Randall JC, Winkler TW, Qi L, Steinthorsdottir V, et al. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. *Nat Genet* 2010;**42**:949–960.